First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
=========================================================================================================================================================================================================

* Sarina A Piha-Paul
* Ravit Geva
* Tira J Tan
* Darren WT Lim
* Cinta Hierro
* Toshikiko Doi
* Osama Rahma
* Alexander Lesokhin
* Jason John Luke
* Javier Otero
* Lisa Nardi
* Angad Singh
* Alexandros Xyrafas
* Xinhui Chen
* Jennifer Mataraza
* Philippe L Bedard